Health
UniQure gets review date and adcomm; Inovia's stock surges after approval
Plus news about AbbVie, Gilead and Tiziana Life Sciences. FDA gives uniQure a review date and adcomm: The agency will decide whether or not to approve UniQure’s high-profile Huntington’s disease gene therapy by May 1 ...
- Published
- (52 min ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 36-word snippet. The full article is at the source.
More from Endpoints News and around the same time
Karyopharm plans to merge with Ayrmid, the company that tried buying bluebirdWith few options remaining, a commercial-stage blood cancer biotech will go through a bankruptcy process and plans to merge with another drugmaker in the blood disorder field. Karyopharm Therapeutics, maker of the multiple…FDA puts Bright Minds drug on partial hold, stock tanksThe FDA placed an experimental seizure drug from Bright Minds Biosciences on a partial clinical hold, the company announced Monday. Regulators issued the hold for BMB-101 after identifying toxicity issues in preclinical mouse…CinRx teams with Sam Waksal's Graviton on ROCK2 for PAH, other cardio conditionsSam Waksal is doubling down on ROCK2 after his first work on the target led to the chronic graft-versus-host disease medicine Rezurock. Now, the Graviton Bioscience CEO is teaming up with a cardio drug development ...Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and moreHello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but just noting that they’re actually made with bug secretions. The Atlantic has all ...Sanofi may seek higher European drug prices, not withhold launches, under Trump dealWhile some of Europe’s biggest drugmakers have warned that President Donald Trump’s pricing policies could leave European patients waiting longer for new medicines, Sanofi is taking a different approach. ...Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed backPlus news about Acumen, Bristol Myers Squibb, Regeneron, Aer Therapeutics and Hemay Pharmaceutical. Gilead pauses CAR-T after ICANS: After several cases of the neurological condition known as ICANS, Gilead said in ...This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
